Skip to main content Skip to navigation
Make an Appointment Today 1-888-884-BEAR (2327) 1-888-884-BEAR (2327)
Find a Doctor Donate
Call Us Menu
We care about your privacy. Read about your rights and how we protect your data. Get Details
More on this Topic

COVID-19 Update:Learn more about how we are protecting our patients, families and staff, as well as other important facts about COVID-19.

Reuven Schore, MD

Oncologist Make an Appointment

Play video
View More Videos

Locations

Education & Training

  • Fellowship, Pediatric Hematology-Oncology, 2006
    Cincinnati Children's Hospital Medical Center
  • Residency, Pediatrics, 2003
    North Shore University Hospital GME-Manhasset
  • Internship, Pediatrics, 2001
    North Shore University Hospital GME-Manhasset
  • MD, 2000
    SUNY Downstate Health Sciences University
  • BA, 1995
    Brooklyn College

Board Certifications

  • American Board of Pediatrics
  • American Board of Pediatrics/Hematology-Oncology

National Provider ID: 1033204227

Biography

Reuven Schore, M.D., is a pediatric oncologist and a member of the Leukemia/Lymphoma Program at Children's National Hospital.

Dr. Schore is the vice chair for a Children's Oncology Group study investigating intravenous treatments for patients with high-risk acute lymphoblastic leukemia (ALL).

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

Outside Interests

  • Sigma Tau Pharmaceuticals 
  • Merck, Sharpe & Dohme Corporation 
  • Millenium Pharmaceuticals 


Research & Publications

Alteration of RhoH expression is associated with human diffuse large B-cell lymphoma

(2005) The 6th International Symposium and Expert Workshops on Leukemia and Lymphoma

Inhibition of the Rho GTPase Rac differentially inhibits proliferation of AML cell lines and may serve as a novel molecular target

(2005) American Society of Hematology Annual Meeting

Inhibition of the Rho GTPase Rac differentially inhibits proliferation of AML cell lines and may serve as a novel molecular target

(2006) 8th Annual OSU Comprehensive Cancer Center Scientific Meeting

Rac a Member of the Rho GTPase Family Is a Potential Target in AML

(2006) Fourth Annual Midwest Blood Club Meeting

Rac Guanosine Triphosphatases represent a potential target in AML

(2008) Leukemia